| Name | Title | Contact Details |
|---|
D-EDGE helps 17,000 hoteliers maximise their revenue from marketing and distribution. Discover our hotel technology: Central Reservation System (CRS), Booking Engine & Channel Manager, Big Data for hotels, Hotel Website Design, Digital Marketing, and m...
Traffk is focused on re-engineering the basic building blocks of insurance, beginning with underwriting. Traffk provides alternative insurance data that boost predictive accuracy in modeling and actuarial development, underwriting, and internal inter-d...
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
ValueClick, Inc. is one of the leading providers in Software and Internet. It is based in Thousand Oaks, CA. To find more information about ValueClick, Inc., please visit www.valueclick.com.